Publications by authors named "Michael Milhollen"

Claim this Profile
P
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.
Wassilis S C Bruins, Rosa Rentenaar, John Newcomb, Wenrou Zheng, Ruud W J Ruiter, Michael Milhollen

Hemasphere· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
Eric S Lightcap, Pengfei Yu, Stephen Grossman, Keli Song, Mithun Khattar, Michael A Milhollen

Sci Transl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Samir H Barghout, Parasvi S Patel, Xiaoming Wang, G Wei Xu, Simon Kavanagh, Michael Milhollen

Leukemia· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Marc L Hyer, Michael A Milhollen, Jeff Ciavarri, Paul Fleming, Tary Traore

Nat Med· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
Amir A Jazaeri, Etsuko Shibata, Jonghoon Park, Jennifer L Bryant, Mark R Conaway, Michael A Milhollen

Mol Cancer Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
Steffan T Nawrocki, Kevin R Kelly, Peter G Smith, Claudia M Espitia, Anthony Possemato, Michael Milhollen

Clin Cancer Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
Jonathan L Blank, Xiaozhen J Liu, Katherine Cosmopoulos, David C Bouck, Khristofer Garcia, Michael A Milhollen

Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and application of NEDD8 E1 inhibitors.
Frank J Bruzzese, Michael A Milhollen, James M Gavin, Helen R Josephine, James E Brownell

Methods Mol Biol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
Michael A Milhollen, Michael P Thomas, Usha Narayanan, Tary Traore, Jessica Riceberg

Cancer Cell· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues.
Jesse J Chen, Christopher A Tsu, James M Gavin, Michael A Milhollen, Frank J Bruzzese

J Biol Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.
Michael A Milhollen, Usha Narayanan, Teresa A Soucy, Petter O Veiby, Peter G Smith

Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
Jie Jessie Lin, Michael A Milhollen, Peter G Smith, Usha Narayanan, Anindya Dutta

Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Michael A Milhollen, Tary Traore, Jennifer Adams-Duffy, Michael P Thomas, Allison J Berger

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.
Teresa A Soucy, Lawrence R Dick, Peter G Smith, Michael A Milhollen, James E Brownell

Genes Cancer· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
James E Brownell, Michael D Sintchak, James M Gavin, Hua Liao, Frank J Bruzzese, Michael A Milhollen

Mol Cell· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Teresa A Soucy, Peter G Smith, Michael A Milhollen, Allison J Berger, James M Gavin

Nature· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Naoki Agata, Hiroko Nogi, Michael Bamberg, Michael Milhollen, Minying Pu

Cancer Chemother Pharmacol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
Naoki Agata, Hiroko Nogi, Michael Milhollen, Surender Kharbanda, Donald Kufe

Cancer Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Corinne L Reimer, Naoki Agata, Jennifer G Tammam, Michael Bamberg, William M Dickerson, Michael Milhollen

Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis